As per the agreement, Genetic Technologies will become the distributor in Australia, Indonesia, Malaysia, the Philippines, Singapore and Thailand.

ResponseDX tests are proprietary PCR-based tests used to analyze the expression of genes that correlate with response to commonly used chemotherapy agents. By personalizing care based on a tumor’s genetic makeup, ResponseDX tests can help physicians to better tailor treatment for their patients with cancer, said the company.

ResponseDX genetic tests are available in the US through direct sales and through NeoGenomics Laboratories, the national clinical reference laboratory authorized to offer Response Genetics’ proprietary tests.

Kathleen Danenberg, CEO and president of Response Genetics, said: “We are pleased to partner with Genetic Technolgies to make our ResponseDX tests available there, as well as in certain Asian countries. Together we hope to reduce the social and economic burdens of this devastating disease as more people have an opportunity to experience the benefits of our personalized medicine approach.”